

30-1120: Anti-CD16 / FcγRIII Monoclonal Antibody (Clone:MEM-154)

Clonality :	Monoclonal
Clone Name :	MEM-154
Application :	FACS
Reactivity :	Human
Gene :	FCGR3A
Gene ID :	2214
Uniprot ID :	P08637
Format :	Purified
Alternative Name :	FCGR3A,CD16A,FCG3,FCGR3,IGFR3
Isotype :	Mouse IgG1
Immunogen Information :	Human granulocytes

Description

CD16 (FcγRIII) is a 50-65 kDa glycoprotein serving as a low affinity IgG receptor. Human FcγRIII is expressed in two forms - FcγRIII-A and -B. FcγRIII-A is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. It is associated with FcεRI-gamma subunit and is responsible for antibody-dependent NK cell cytotoxicity. Mast cell FcγRIII-A is associated, moreover, with FcεRI-beta subunit. Besides IgG, FcγRIII-A can be triggered also by oligomeric IgE. FcγRIII-B is a GPI-linked monomeric receptor expressed on neutrophils and is involved in their activation and induction of a proadhesive phenotype.

Product Info

Amount :	0.1 mg
Purification :	Purified by protein-A affinity chromatography
Storage condition :	Store at 2-8°C. Do not freeze.

Application Note

Flow Cytometry *Recommended dilution:* 5-10 µg/ml

Positive control: PBL (peripheral blood lymphocytes)

Application note: The antibody MEM-154 does not react with CD16a present on NK cells in many subjects.

Immunoprecipitation Western Blotting *Application note:* Non-reducing conditions. **Functional Application** The antibody MEM-154 blocks binding of human IgG to FcγRIII.




Figure 1: Flow cytometry surface staining pattern of human peripheral blood stained using anti-human CD16 (MEM-154) purified antibody (concentration in sample 2 1 4g/ml) GAM APC.




Figure 2: Separation of FasL transfected L5178Y cells stained using anti-human CD178 (NOK-1) purified antibody (concentration in sample 9 1 4g/ml, GAM APC, red-filled) from FasL transfected L5178Y cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining).